US Stock Insider Trading | Theravance Discloses 5 Insider Transactions on February 24

K-LinePoet · 2026-03-07T07:14:12+00:00

Theravance disclosed multiple insider transactions on February 24, 2026. Director Winningham Rick E sold 75,000 shares on February 20, and other executives also sold shares, totaling several million dollars. The company focuses on drug development and is committed to improving patients' lives.

K-LinePoet

2026-03-07 07:14:12

Abstract generation in progress

On February 24, 2026, Theravance (TBPH) disclosed five insider transactions. Director Winningham Rick E sold 75,000 shares on February 20, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 24, 2026	Director	Winningham Rick E	February 20, 2026	Sell	75,000	19.66	1.474 million
February 24, 2026	Executive	Sawaf Aziz	February 20, 2026	Sell	20,700	19.66	406,400
February 24, 2026	Executive	Miller Aine	February 20, 2026	Sell	16,900	19.66	331,300
February 24, 2026	Executive	Farnum Rhonda	February 20, 2026	Sell	13,900	19.66	273,800
February 24, 2026	Executive	Grimaud Brett A.	February 20, 2026	Sell	20,800	19.66	409,600
December 5, 2025	Executive	Farnum Rhonda	December 3, 2025	Sell	7,766	18.75	145,600
December 5, 2025	Executive	Farnum Rhonda	December 3, 2025	Sell	7,767	18.75	145,600
December 5, 2025	Executive	Farnum Rhonda	December 3, 2025	Sell	15,500	18.75	291,300
December 1, 2025	Director	BROSHY ERAN	November 26, 2025	Sell	29,500	20.00	590,000
November 24, 2025	Executive	Miller Aine	November 20, 2025	Sell	6,989	17.90	125,100

[Company Information]

Theravance Biopharma, Inc., incorporated in July 2013 as a Cayman Islands exempted company. The company is a biopharmaceutical firm primarily focused on the discovery, development, and commercialization of drugs. Its core mission is to create medicines that can change people’s lives. Leveraging decades of expertise, the company developed FDA-approved YUPELRI (revefenacin) inhalation solution for maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.